Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Oertel, Wolfgang H; Hallström, Yngve; Saletu-Zyhlarz, Gerda M; Hopp, Michael; Bosse, Björn; Trenkwalder, Claudia; RELOXYN Study Group; Högl, B; Röper, C; Saletu-Zyhlarz, G; Behrens, S; Bene?, H; Bergtholdt, B; Bitter, R; Bodenschatz, R; Böhringer, J; Boldt, H-J; Braune, S; Donat, P; Fietze, I; Franz, P; Geisler, P; Gertz, H-J; Gestewitz, B; Haan, J; Happe, S; Henin, H; Hornyak, M; Hufnagel, A; Kallmann, B-A; Karlbauer, G; Kassubek, J; Klein, M; Koppai-Reiner, J; Lang, M; Leibinger, R; Lüer, W; Lünser, W; Mahler, A; Mattern, W; Mayer, G; Molt, W; Oertel, W; Peglau, I; Peltz, J; Rüttgers, E; Sallach, K; Schöll, I; Schulze, A; Schumann, V; Siefjediers, V; Siever, A; Sigel, K-O; Simonow, A; Sixel-Döring, F; Sloksnat, R; Sommer, H; Springub, J; Spieker, T; Steinwachs, K-C; Stiasny-Kolster, K; Stierstorfer, A; Storch, A; Tinschert, K; Trenkwalder, C; Veit, B; Warmuth, R; Young, P; Zuchner, D; García-Borreguero, D; Iranzo de Riquer, A; Martinez Rodriguez, JE; Puertas, FJ; Romero Santo-Tomás, O; Grote, L; Hallström, Y; Markström, A

doi:10.1007/s40263-016-0372-1

User: Guest

2016

Back
Back to start of result list
Permanent link for displayed object

Title:: Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.
Document type:: journal article
Author(s):: Oertel, Wolfgang H; Hallström, Yngve; Saletu-Zyhlarz, Gerda M; Hopp, Michael; Bosse, Björn; Trenkwalder, Claudia; RELOXYN Study Group; Högl, B; Röper, C; Saletu-Zyhlarz, G; Behrens, S; Bene?, H; Bergtholdt, B; Bitter, R; Bodenschatz, R; Böhringer, J; Boldt, H-J; Braune, S; Donat, P; Fietze, I; Franz, P; Geisler, P; Gertz, H-J; Gestewitz, B; Haan, J; Happe, S; Henin, H; Hornyak, M; Hufnagel, A; Kallmann, B-A; Karlbauer, G; Kassubek, J; Klein, M; Koppai-Reiner, J; Lang, M; Leibinger, R; Lüer, W; Lünser, W; Mahler, A; Mattern, W; Mayer, G; Molt, W; Oertel, W; Peglau, I; Peltz, J; Rüttgers, E; Sallach, K; Schöll, I; Schulze, A; Schumann, V; Siefjediers, V; Siever, A; Sigel, K-O; Simonow, A; Sixel-Döring, F; Sloksnat, R; Sommer, H; Springub, J; Spieker, T; Steinwachs, K-C; Stiasny-Kolster, K; Stierstorfer, A; Storch, A; Tinschert, K; Trenkwalder, C; Veit, B; Warmuth, R; Young, P; Zuchner, D; García-Borreguero, D; Iranzo de Riquer, A; Martinez Rodriguez, JE; Puertas, FJ; Romero Santo-Tomás, O; Grote, L; Hallström, Y; Markström, A «
Oertel, Wolfgang H; Hallström, Yngve; Saletu-Zyhlarz, Gerda M; Hopp, Michael; Bosse, Björn; Trenkwalder, Claudia; RELOXYN Study Group; Högl, B; Röper, C; Saletu-Zyhlarz, G; Behrens, S; Bene?, H; Bergtholdt, B; Bitter, R; Bodenschatz, R; Böhringer, J; Boldt, H-J; Braune, S; Donat, P; Fietze, I; Franz, P; Geisler, P; Gertz, H-J; Gestewitz, B; Haan, J; Happe, S; Henin, H; Hornyak, M; Hufnagel, A; Kallmann, B-A; Karlbauer, G; Kassubek, J; Klein, M; Koppai-Reiner, J; Lang, M; Leibinger, R; Lüer, W; L... »
Abstract:: The aim was to assess the effects of prolonged release oxycodone/naloxone (OXN PR) on sleep and quality of life (QoL) in patients with severe restless legs syndrome (RLS) refractory to first-line dopaminergic RLS treatment.Sleep and QoL data from a 12-week, randomized, double-blind, placebo-controlled study with subsequent 40-week, open-label extension were analyzed. Instruments included the Medical Outcomes Study (MOS) sleep scale, RLS-6 rating scale, and RLS-QoL questionnaire.The full analysis population included 132 OXN PR and 144 placebo patients. After 12 treatment weeks, improvements in the MOS domains'sleep disturbance' [-18.6; 95 % confidence interval (CI) -24.4 to -12.9; p< 0.0001],'sleep adequacy' (14.9; 95 % CI 7.9-21.9; p< 0.0001), and'sleep quantity' (0.77 h; 95 % CI 0.43-1.11; p< 0.0001) were significantly greater under OXN PR than under placebo. OXN PR also reduced symptom severity (when falling asleep and during the night) and daytime tiredness, and increased sleep satisfaction to a significantly greater extent than placebo (all p< 0.001; RLS-6). QoL improved in both treatment arms, with a significant difference of -9.02 (95 % CI -12.85 to -5.19; p< 0.001) in the mean sum score in favor of OXN PR. All sleep and QoL aspects also improved under 40 weeks of open-label OXN PR treatment.OXN PR improved RLS symptom severity and sleep quantity and adequacy, resulting in greater sleep satisfaction, less daytime tiredness, and improved QoL. In appropriate patients, OXN PR should be considered as an alternative treatment option for severe RLS that cannot be controlled by first-line dopaminergic medications.ClinicalTrials.gov (NCT01112644) and EudraCT (2009-011107-23).
Journal title abbreviation:: CNS Drugs
Year:: 2016
Journal volume:: 30
Journal issue:: 8
Pages contribution:: 749-60
Language:: eng
Fulltext / DOI:: doi:10.1007/s40263-016-0372-1
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/27401882
Print-ISSN:: 1172-7047
TUM Institution:: Neurologische Klinik und Poliklinik
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Neurologie (Prof. Hemmer)2016